10
ALL10
BlueRock Therapeutics
Year
10
ALL1
20253
20241
20233
20222
2021
DEALS // DEV.
10
ALL10
Developments
Country
10
ALL10
U.S.A
10
ALL4
Bayer AG5
Inapplicable1
Memorial Sloan Kettering Cancer Center
Therapeutic Area
10
ALL10
Neurology
Study Phase
10
ALL5
Phase II5
Phase I
Deal Type
10
ALL10
Inapplicable
Product Type
10
ALL10
Cell and Gene therapy
Dosage Form
10
ALL10
Intracerebral Injection
Lead Product
10
ALL5
Bemdaneprocel5
DA01
Target
10
ALL5
Dopaminergic cell5
Undisclosed
BlueRock Therapeutics Advances Bemdaneprocel to Phase III Trial for Parkinson’s
Details : BRT-DA01 (bemdaneprocel) is an investigational allogeneic stem cell derived cell therapy designed to replace the dopamine producing neurons that are lost in Parkinson’s disease.
Product Name : BRT-DA01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 13, 2025
BlueRock’s Bemdaneprocel Shows Positive Data at 24 Months for Parkinson’s Disease
Details : Bemdaneprocel (BRT-DA01) is an investigational allogeneic stem cell derived cell therapy designed to replace the dopamine producing neurons that are lost in Parkinson’s disease.
Product Name : BRT-DA01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 27, 2024
BlueRock's Phase I Trial for Parkinson’s Shows Positive Trends at 18 Months
Details : Bemdaneprocel (BRT-DA01) is an investigational allogeneic stem cell derived cell therapy designed to replace the dopamine producing neurons that are lost in Parkinson’s disease.
Product Name : BRT-DA01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 03, 2024
BlueRock Therapeutics Gets FDA RMAT Designation for Parkinson’s Disease Cell Therapy
Details : Bemdaneprocel (BRT-DA01) is an investigational allogeneic stem cell derived cell therapy designed to replace the dopamine producing neurons that are lost in Parkinson’s disease.
Product Name : BRT-DA01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 31, 2024
Details : BRT-DA01 (bemdaneprocel) is an investigational therapy comprised of dopamine producing neurons derived from pluripotent stem cells, is surgically implanted into the brain of a person with Parkinson’s disease.
Product Name : BRT-DA01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 10, 2023
Details : The primary objective of the Ph1 trial is to assess the safety and tolerability of DA01 cell transplantation at one-year post-transplant. The secondary objectives, are to assess the evidence of transplanted cell survival and motor effects at one and two-...
Product Name : DA01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 01, 2022
Details : The primary objective of the Ph1 trial is to assess the safety and tolerability of BRT-DA01 transplantation at one-year post-transplant. The secondary objectives are to assess the evidence of transplanted cell survival and motor effects at one- and two-y...
Product Name : DA01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 31, 2022
Details : The purpose of the Ph1 clinical trial is to evaluate the safety, tolerability and preliminary efficacy of DA01. DA01 is being clinically evaluated in a subset of patients with advanced Parkinson’s disease, where regular medications are no longer fully ...
Product Name : DA01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 18, 2022
Details : Based on safety, tolerability, and the immune response generated by 144 children in the Phase I study of the two-dose shot, Pfizer will test a dose of BNT162b2 10mg in children between 5-11 years, and 3mg for the age group of 6-5 years old.
Product Name : DA01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 06, 2021
BlueRock Therapeutics Receives FDA Fast Track Designation for DA01
Details : The primary objective of the Ph1 study is to assess the safety and tolerability of DA01 cell transplantation at one-year post-transplant.
Product Name : DA01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 19, 2021
Reset All
